AbbVie buys ImmunoGen for $10.1 billion, expanding cancer drug portfolio

AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.

Related Keywords

Daiichi Sankyo ,Ceo Richard Gonzalez ,Mark Enyedy ,Emma Gustin ,Barclays ,European Union ,Bristol Myers Squibb ,Astrazeneca ,Pfizer ,Wall Street ,Bristol Myers ,Markets Amp Regulations ,Bio Developments ,Pipelines ,Antibody Drug Conjugates ,Abbvie ,Dc ,Merck ,